Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States

Paul A. Greenberger; Mark Ballow; Thomas B. Casale; Thomas A.E. Platts-Mills; Hugh A. Sampson

doi:10.1016/j.jaci.2007.08.055

Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States

Paul A. Greenberger, Mark Ballow, Thomas B. Casale, Thomas A.E. Platts-Mills, Hugh A. Sampson

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English
Pages (from-to)	1466-1468
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology
Volume	120
Issue number	6
DOIs	https://doi.org/10.1016/j.jaci.2007.08.055
State	Published - Dec 2007

Access to Document

10.1016/j.jaci.2007.08.055

Cite this

@article{35eb30128ff14528a0946ccf5a9e4e9e,

title = "Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States",

author = "Greenberger, {Paul A.} and Mark Ballow and Casale, {Thomas B.} and Platts-Mills, {Thomas A.E.} and Sampson, {Hugh A.}",

note = "Funding Information: Disclosure of potential conflict of interest: P. A. Greenberger has consulting arrangements with Novartis and has received grant support from the National Heart, Lung, and Blood Institute. M. Ballow has consulting arrangements with Talecris Therapeutics and is on the speakers' bureau for Merck and AstraZeneca. T. B. Casale has consulting arrangements with Dynavax and has received grant support from Dynavax, Curalogic, and Allergy Therapeutics. T. A. E. Platts-Mills has consulting arrangements with Indoor Biotechnologies and has received grant support from the National Institute of Allergy and Infectious Diseases. H. A. Sampson has consulting arrangements with Allertein. ",

year = "2007",

month = dec,

doi = "10.1016/j.jaci.2007.08.055",

language = "English",

volume = "120",

pages = "1466--1468",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "6",

}

TY - JOUR

T1 - Sublingual immunotherapy and subcutaneous immunotherapy

T2 - Issues in the United States

AU - Greenberger, Paul A.

AU - Ballow, Mark

AU - Casale, Thomas B.

AU - Platts-Mills, Thomas A.E.

AU - Sampson, Hugh A.

N1 - Funding Information: Disclosure of potential conflict of interest: P. A. Greenberger has consulting arrangements with Novartis and has received grant support from the National Heart, Lung, and Blood Institute. M. Ballow has consulting arrangements with Talecris Therapeutics and is on the speakers' bureau for Merck and AstraZeneca. T. B. Casale has consulting arrangements with Dynavax and has received grant support from Dynavax, Curalogic, and Allergy Therapeutics. T. A. E. Platts-Mills has consulting arrangements with Indoor Biotechnologies and has received grant support from the National Institute of Allergy and Infectious Diseases. H. A. Sampson has consulting arrangements with Allertein.

PY - 2007/12

Y1 - 2007/12

UR - http://www.scopus.com/inward/record.url?scp=36749095849&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2007.08.055

DO - 10.1016/j.jaci.2007.08.055

M3 - Letter

C2 - 17936891

AN - SCOPUS:36749095849

SN - 0091-6749

VL - 120

SP - 1466

EP - 1468

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6

ER -